Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
  • Word abonnee
  • Inloggen

    Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?
Home  /  Forum  /  MDxHealth  /  MDxHealth Receives 2011 European Molecular Diagnostics for Oncology Technology Leadership Award

Ontvang nu dagelijks onze kooptips!

word abonnee

MDxHealth Receives 2011 European Molecular Diagnostics for Oncology Technology Leadership Award

364 Posts
Pagina: 1 2 3 4 5 6 ... 19 »» | Laatste | Omlaag ↓
  1. [verwijderd] 9 januari 2012 18:53
    MDxHealth Receives 2011 European Molecular Diagnostics for Oncology Technology Leadership Award

    IRVINE, CA, and LIEGE, BELGIUM – January 9, 2012 – MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostics company in the field of personalized cancer treatment, announced today the receipt of the Frost & Sullivan 2011 European Molecular Diagnostics for Oncology Technology Leadership award. In giving the awards, Frost & Sullivan recognizes the strength and broad applicability of MDxHealth’s epigenetic technology platform in generating advanced tests for cancer assessment and the personalized treatment of patients.

    “It is a great honor to receive this award from Frost & Sullivan,” noted Dr. Jan Groen, CEO of MDxHealth. “Our proprietary epigenetic technology, for which we are being recognized, forms the basis of all of our innovative cancer tests. It is good to see the hard work and dedication of all our employees being acknowledged independently.”

    In bestowing the award, Frost & Sullivan Senior Research Analyst Cecilia Van Cauwenberghe said: “MDxHealth’s tests help distinguish between different levels of drug responders, while helping to accelerate the pharmaceutical development of a variety of drug therapies and demonstrating higher drug efficacy rates. Such new dynamic work styles enable the companies to overcome regulatory issues expediently, while simultaneously diminishing drug discovery and development costs.”

    More information on the Award can be found on the Frost & Sullivan website: www.frost.com/prod/servlet/press-rele...

    About MDxHealth
    MDxHealth is a leading molecular diagnostics company that develops and commercializes oncology-based molecular diagnostic testing for personalized medicine. The company’s tests are based on proprietary gene methylation technology and assist physicians with the diagnosis of cancer, prognosis of recurrence risk, and prediction of response to a specific therapy. For more information visit the MDxHealth website at www.mdxhealth.com.

    MDxHealth was recently profiled in the recent PWC Diagnostics 2011 report. The profile highlights the company’s change in strategy towards being a product based company that was implemented during 2011. Details of the report can be found on the PWC website (http://www.pwc.com/diagnostics2011).

    Biotech Showcase 2012, January 9-11, San Francisco – Dr. Jan Groen will be presenting at the Biotech Showcase conference. Parties interested in meeting can contact Dr. Groen at the following : info@mdxhealth.com.

    More information:
    Dr. Jan Groen, CEO Mike Sinclair
    MDxHealth Halsin Partners
    +32 4 364 20 70 +44 20 7318 2955
  2. [verwijderd] 9 januari 2012 18:54
    Frost & Sullivan Applauds MDxHealth for its Proprietary Epigentic DNA-based Technology that Accelerates Cancer Diagnostic Development and Personalizes Therapeutics

    MDxHealth's technology drives proprietary product development; prostate cancer confirmation test to be commercialized in 1H2012 London UK - January 9, 2012 - Based on its recent analysis of the molecular diagnostics for oncology market, Frost & Sullivan recognizes MDxHealth with the 2011 Europe Frost & Sullivan Award for Technology Leadership. MDxHealth's epigenetic platform, the methylation-specific-polymerase chain reaction (PCR) (MSP), can detect the presence of a single cancer cell from almost 10,000 cells with high accuracy and specificity.

    Read the full details on frost.com

  3. [verwijderd] 9 januari 2012 18:56
    Frost & Sullivan Applauds MDxHealth for its Proprietary Epigentic DNA-based Technology that Accelerates Cancer Diagnostic Development and Personalizes Therapeutics


    Date Published: 9 Jan 2012

    MDxHealth's technology drives proprietary product development; prostate cancer confirmation test to be commercialized in 1H2012

    London UK - January 9, 2012 - Based on its recent analysis of the molecular diagnostics for the oncology market, Frost & Sullivan recognizes MDxHealth with the 2011 Europe Frost & Sullivan Award for Technology Leadership. MDxHealth's epigenetic platform, the methylation-specific-polymerase chain reaction (PCR) (MSP), can detect the presence of a single cancer cell from almost 10,000 cells with high accuracy and specificity.

    MDxHealth's platform offers physicians a novel molecular gene-based technology that uses individual genes as DNA biomarkers and methylation-based molecular diagnostics (MDx) to identify certain gene modifications caused by the presence of cancerous cells. By leveraging the importance of a platform-independent approach, the company has gained expertise in working with a broad spectrum of PCR platforms and therefore, is able to perform assays on a variety of commonly used devices.

    MDxHealth works on two principal applications categories: clinical diagnostics, aimed at helping physicians accurately detect and offer prognosis, and pharmaco diagnostics, aimed at assisting pharmaceutical companies in developing companion diagnostics for multiple cancer therapeutics.

    The company provides a combination of the most appropriate assays for each type of cancer. Its three main product categories are ConfirmMDx, to determine of the presence or absence of cancer cells; InformMDx, to provide prognostic assessment in distinguishing between aggressive and non-aggressive tumours; and PredictMDx, to indicate which drug or treatment regimen should be addressed to accomplish an effective therapy.

    "MDxHealth's tests help distinguish between different levels of drug responders, while helping to accelerate the pharmaceutical development of a variety of drug therapies and demonstrating higher drug efficacy rates," said Frost & Sullivan Senior Research Analyst Cecilia Van Cauwenberghe. "Such new dynamic work styles enable the companies to overcome regulatory issues expediently, while simultaneously diminishing drug discovery and development costs."

    The company also drives a pharmaco molecular diagnostics programme focused on providing innovative biomarker development services to Biopharma companies to support their drug development programmes and improve their results. MDxHealth's ability to develop and validate highly customized assays significantly helps meet partners' needs in their R&D programmess by offering them a reliable and high-performance technology.

    MDxHealth's DNA preparation process adheres to a strict quality policy that governs each step of the process. It is this attention to detail that has enabled it to meet ISO 9001 specifications and own the most widely used and cited methylation detection technology in the world.

    Another factor that has contributed significantly to MDxHealth's success is its strong IP portfolio, which comprises more than 40 issued patents in multiple countries. The company has established a solid out-licensing and partnering policy by offering numerous opportunities to specialized third-party companies. By this arrangement, the third-party companies can draw up different licensing agreements for some of its technology components to develop applications not pursued by MDxHealth.

    Licensing opportunities are open for screening and recurrence monitoring of bladder cancer, colorectal cancer screening, cervical cancer screening and triage, melanoma, ovarian, lung, and breast cancer, in addition to non-cancer diseases that can make use of the DNA methylation process for their diagnosis.

    The company's business strategy and its commitment to providing ground-breaking solutions have given a huge boost to its growth rates. In 2010 alone, MDxHealth generated over €2.0 million in product sales and services agreements, which was an increase of 91 per cent over 2009. It gained this competitive edge and market position through strategic investments in technology and business development.

    "The company also made a conscious effort to move away from a discovery/license model to a commercial/sales model, and consolidated a strengthened advisory board and management team," noted Van Cauwenberghe. "MDxHealth maintains a strong partnership and collaborations policy, leveraging the robust IP position of the proprietary technology, extensive pipeline, high quality and performance, growing market, clear commercial strategy and profitability to remain successful."

    Each year, Frost & Sullivan presents this award to the company that demonstrated excellence in technology leadership within its industry by excelling in all stages of the technology life cycle - incubation, adaptation, take up, and maturity - to ensure a continuous flow of improvements. By innovating leading-edge concepts the company has pioneered client applications.

    Frost & Sullivan Best Practices awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research to identify best practices in the industry.

    About MDxHealth

    MDxHealth is a molecular diagnostics company that develops and commercializes advanced tests for cancer assessment and the personalized treatment of patients. MDxHealth is a publicly-listed company trading on the NYSE Euronext markets of Brussels and Amsterdam under the ticker symbol "MDXH". MDxHealth was established in 2003 and is headquartered in Belgium. Its US headquarters is located in Irvine, CA. MDxHealth develops and commercialize molecular diagnostic products on its own or in partnership with pharmaceutical companies. Some of its products are already commercialized and the company has a broad pipeline of other products for major cancer indications. For more information visit the MDxHealth website at www.mdxhealth.com

    About Frost & Sullivan

    Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages 50 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 40 offices on six continents. To join our Growth Partnership, please visit www.frost.com.

    Contact:

    Emily Bailey
    Promotions
    Frost & Sullivan
    emily.bailey@frost.com
    P: +44 (0)20 7915

    www.frost.com/prod/servlet/press-rele...

    www.mdxhealth.com/news-and-events/pre...
  9. Debit or Credit 10 januari 2012 18:37
    NEL ik zie je graag bij Mdx. ICT staat al tijden op mijn watchlist maar gezien de nog onzekere markt zie ik ze nog niet zo snel stijgen.... Macintosh wordt ook flink afgeslacht en ook daar kan nog een paar euro af. Morgen maar eens mdx naar boven laten knallen!

    Hier even de karige laat:

    1.63 4,746
    1.65 6,000
    1.66 2,043
    1.70 950
    1.73 2,850
    1.74 4,300
    1.75 4,676
    1.78 3,074
    1.89 2,535
    1.90 5,900

    DoC.
  10. Debit or Credit 11 januari 2012 09:01
    Laat voor vandaag met ontzettende gaps!

    1.63 4,646
    1.65 6,000
    1.70 950
    1.73 2,850
    1.74 800
    1.75 4,676
    1.78 3,074
    1.89 2,535
    1.90 5,900
    1.91 13,500

    Morgen een perbericht met betrekking tot verkoop van de prostaatkankertesten en de koers zal omhoog knallen.

    Vandaag de laatste dag om een mooie kans te maken op een mooie rit!

    Ik hoor het van jullie.

    Met vriendelijke groet,

    DoC.
  11. drulletje drie 11 januari 2012 09:24
    Gisteravond gekeken en het ziet er inderdaad allemaal heel hoopvol uit!
    Wat ik ook een voordeel vind is dat het niet om een medicijn gaat dus kans op geen goedkeuring en dus koersval is er niet!

    Patenten zien er succesvol uit dus het is inderdaad wachten op nieuws maar wanneer....
  12. Debit or Credit 11 januari 2012 09:40
    @ drul, klopt inderdaad. Er komt deze week nog nieuws omtrent mdx. De eerste verkopen van de prostaatkankertest beginnen er aan te komen. De grote pharmareuzen worden onder druk gezet om als eerste voor een zo laag mogelijke prijs de patenten van mdx over te nemen. Echter is de concurrentie in deze markt groot, wat voor de mdx aandeelhouder velen voordelen bied mbt tot het krijgen van een zeer goede prijs voor deze patenten. Glaxo, Pfizer en Celldex zijn een aantal grote spelers die mdx steunen. Nog voldoende cash dus geen emissiegevaar. Ik zie geen reden om geen poging te wagen.. Mocht er iemand anders over denken hoor ik het graag. Alle nuttige info is welkom.

    Met vriendelijke groet,

    DoC.
  14. Debit or Credit 11 januari 2012 11:13
    quote:

    drulletje drie schreef op 11 januari 2012 10:53:

    Het is jammer dat de bied niet oploopt dan krijg je misschien wat koopdruk nu blijft iedereen wachten.
    Zit nu marketmaker op 1,62 die stukken vervallen als er 1,61 geboden wordt. Als de 1,63 opgeheven wordt koop ik alles op 1,65 en dan moet je zorgen dat je erbij bent. Gelijk een freeze naar 1,70+. Anyway ga vanavond eens kijken of ik de bijeenkomst online kan bijwonen.

    DoC.
  16. drulletje drie 11 januari 2012 11:29
    Ik bewonder je positieve benadering DOC echt waar haha!
    Maar als ik eerlijk ben zie ik het niet gebeuren! Er moeten meer kopers komen om dat voor elkaar te krijgen dat gaat je niet in je eentje lukken!
    En voor meer kopers is er helaas nieuws nodig en dat is er nog niet!

    Hou het wel in de gaten misschien kan ik je met een kleine koop helpen.
364 Posts
Pagina: 1 2 3 4 5 6 ... 19 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Premium drie voorbeelden van IEX Premium: de exclusieve content op de site, de app op een smartphone en IEX Magazine.

Benieuwd naar onze analyses en kooptips?

Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!

Word abonnee

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links

Meld u aan voor de dagelijkse Beursupdate

Dagelijks een update van het laatste beursnieuws en beleggingskansen in uw mailbox!